Finance

Beta
Lists
ORIC:NASDAQ
ORIC Pharmaceuticals Inc
$9.92
+4.09%
(+0.39) 1D
Jun 29, 2:49:50 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ORIC...
Open
$9.60
High
$10.08
Low
$9.47
Mkt. cap
1.03B
Avg. vol.
1.80M
Volume
589.52K
52-wk high
$14.93
52-wk low
$7.23
EPS
-$1.43
Beta
1.04
Shares outstanding
103.52M
No. of employees
104
Open
$9.60
High
$10.08
Low
$9.47
Mkt. cap
1.03B
Avg. vol.
1.80M
Volume
589.52K
52-wk high
$14.93
52-wk low
$7.23
EPS
-$1.43
Beta
1.04
Shares outstanding
103.52M
No. of employees
104
News stories
From sources across the web
About ORIC Pharmaceuticals Inc
CEO-
Employees104
Founded2014
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiteoricpharma.com
Analyst ratings
Based on 11 analysts giving stock ratings to ORIC in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ORIC in the last 3 months.
Highest
Current $9.92
$25.00 (+152.02%)
Average
$20.20 (+103.63%)
Lowest
$14.00 (+41.13%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$22.00
+121.8%
06/29/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$25.00
+152%
06/24/2026
Laura Prendergast
Stifel Nicolaus
Buy
Initiated
$14.00
+41.1%
06/12/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$25.00
+152%
06/11/2026
Corinne Johnson
Goldman Sachs
Buy
Reiterated
$15.00
+51.2%
06/02/2026
Unknown Analyst
Wedbush
Buy
Initiated
$17.00
+71.4%
05/05/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$15.00
+51.2%
05/05/2026
Boris Peaker
JonesTrading
Buy
Maintained
$25.00
+152%
05/05/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$18.00
+81.5%
05/04/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$16.00
+61.3%
05/05/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
04/13/2026
Soumit Roy
JonesTrading
Buy
Maintained
$25.00
+152%
04/06/2026
Danya Ben-Hail
JonesTrading
Buy
Reiterated
$25.00
+152%
04/01/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$25.00
+152%
04/01/2026
David Nierengarten
Wedbush
Buy
Maintained
$20.00
+101.6%
02/24/2026
Last report
May 4, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.34 / -$0.32
-5.99%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
30.55M
28.77M
25.86M
31.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.52M
7.90M
8.70M
8.18M
Operating expense
39.06M
36.67M
34.55M
39.62M
Total operating expenses
39.06M
36.67M
34.55M
39.62M
Operating income
-39.06M
-36.67M
-34.55M
-39.62M
Other non operating income
-
-
-
-
EBT including unusual items
-36.36M
-32.59M
-30.50M
-35.77M
EBT excluding unusual items
-36.36M
-32.59M
-30.50M
-35.77M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36.36M
-32.59M
-30.50M
-35.77M
Net profit margin
-
-
-
-
Earnings per share
-0.47
-0.33
-0.30
-0.34
Interest and investment income
2.71M
4.08M
4.05M
3.85M
Interest expense
-
-
-
-
Net interest expenses
2.71M
4.08M
4.05M
3.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-38.75M
-36.38M
-34.23M
-39.35M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ORIC
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer